Journal article
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors
Abstract
PURPOSE: Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitinib, a potent oral IGF1R/INSR inhibitor, with EGFR inhibitor erlotinib.
EXPERIMENTAL DESIGN: This open-label, dose-escalation study …
Authors
Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW
Journal
Clinical Cancer Research, Vol. 22, No. 12, pp. 2897–2907
Publisher
American Association for Cancer Research (AACR)
Publication Date
June 15, 2016
DOI
10.1158/1078-0432.ccr-15-2218
ISSN
1078-0432
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntigens, CDAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDose-Response Relationship, DrugErbB ReceptorsErlotinib HydrochlorideFemaleHumansImidazolesLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedProtein Kinase InhibitorsPyrazinesReceptor, IGF Type 1Receptor, InsulinReceptors, SomatomedinYoung Adult